Abstract
We have analysed Li–Fraumeni syndrome families, previously shown to be negative for mutations in TP53, for mutations to the tumour suppressor genes PTEN and CDKN2. These genes function in cell cycle progression or are mutated in a variety of tumours. We have detected no mutations in the family members tested.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Birch, J. M., Hartley, A. L., Tricker, K. J., Prosser, J., Condie, A., Kelsey, A. M., Harris, M., Morris Jones, P. H., Binchy, A., Crowther, D., Craft, A. W., Eden, O. B., Evans, D. G. R., Thompson, E., Mann, J. R., Martin, J., Mitchell, E. L. D. & Santibanez-Koref, M. F. (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li–Fraumeni families. Cancer Res 54: 1298–1304.
Chen, J., Lindblom, P. & Lindblom, A. (1998) A study of the PTEN/MMAC1 gene in 136 breast cancer families. Hum Genet 102: 124–125.
Foulkes, W. D., Flanders, T. Y., Pollock, P. M. & Hayward, N. K. (1997) The CDKN2A (p16) gene and human cancer. Mol Med 3: 5–20.
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H. Jr, Tucker, M. A. & Dracopoli, N. C. (1994) Germline p16 mutations in familial melanoma. Nature Genet 8: 15–21.
Kamb, A. (1995) Cell-cycle regulators and cancer. TIG 11: 136–140.
Li, F. P., Fraumeni, J. F. Jr, Mulvihill, J. J., Blattner, W. A., Dreyfus, M. G., Tucker, M. A. & Miller, R. W. (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48: 5358–5362.
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H. & Parsons, R. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275: 1943–1947.
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F. Jr, Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. R., Tainsky, M. A. & Friend, S. H. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233–1238.
Myers, M. P., Stolarov, J. P., Eng, C., Li, J., Wang, S. I., Wigler, M. H., Parsons, R. & Tonks, N. K. (1997) P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 94: 9052–9057.
Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Perwez Hussain, S., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., Beach, D. H. & Harris, C. C. (1994) Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 91: 11045–11049.
Quelle, D. E., Zindy, F., Ashmun, R. A. & Sherr, C. J. (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993–1000.
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., Frye, C., Hu, R., Swedlund, B., Teng, D. H. F. & Tavtigian, S. V. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet 15: 356–362.
Tsou, H. C., Teng, DH-F, Li Ping, X., Brancolini, V., Davis, T., Hu, R., Xun Xie, X., Gruener, A. C., Schrager, C. A., Christiano, A. M., Eng, C., Steck, P., Ott, J., Tavtigian, S. V. & Peacocke, M. (1997) The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases. Am J Hum Genet 61: 1036–1043.
Varley, J. M., Evans, D. G. R. & Birch, J. M. (1997a) Li–Fraumeni syndrome: a molecular and clinical review. Br J Cancer 76: 1–14.
Varley, J. M., McGown, G., Thorncroft, M., Santibanez Koref, M. F., Kelsey, A. M., Tricker, K. J., Evans, D. G. R. & Birch, J. M. (1997b) Germline mutations of TP53 in Li–Fraumeni families: an extended study of 39 families. Cancer Res 57: 3245–3252.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Burt, E., McGown, G., Thorncroft, M. et al. Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li–Fraumeni syndrome. Br J Cancer 80, 9–10 (1999). https://doi.org/10.1038/sj.bjc.6690313
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690313
Keywords
This article is cited by
-
The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype
Hereditary Cancer in Clinical Practice (2009)
-
Screening for TP53 rearrangements in families with the Li–Fraumeni syndrome reveals a complete deletion of the TP53 gene
Oncogene (2003)
